Cor­cept miss­es pri­ma­ry end­point in sup­port­ive Cush­ing's syn­drome study

Cor­cept Ther­a­peu­tics an­nounced Wednes­day that its ex­per­i­men­tal treat­ment for Cush­ing’s syn­drome missed the pri­ma­ry end­point in a Phase 3 tri­al in­tend­ed to sup­port its FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER